ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of LI 210 Tumor Cell Growth in Vitro and in Vivo: A New Agent for Clinical Study

Cancer Research

Volumn 51, Issue 20, 1991, Pages 5579-5586

  Taylor, Gordon A ^a,c   Gibson, William ^a   Kimbell, Rosemary ^a   Brown, Melody ^a   Hilary Calvert, A ^a   Judson, Ian R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; FOLINIC ACID; RALTITREXED; THYMIDINE; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; CARRIER PROTEINS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID; GLUTAMATES; LEUKEMIA L1210; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; QUINAZOLINES; SUPPORT, NON-U.S. GOV'T; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0025997350     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jones, T. R., Calvert, A. H., Jackman, A. L., Brown, S. J., Jones, M., and Harrap, K. R. A potent antitumor quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer, 17:11-19,1981.
2. Jackson, R. C., Jackman, A. L., and Calvert, A. H. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lympho-blastoid cells. Biochem. Pharmacol., 32:3783-3790,1983.
3. Pogolotti, A. L., Danenberg, P. V., and Santi, D. V. Kinetics and mechanism of interaction of 10-propargyl-5,8-dideazafolate with thymidylate synthase. J. Med. Chem., 29:478-482,1986.
4. Cheng, Y-C., Dutschman, G. E., Starnes, M. C., Fisher, M. H., Nanavathi, N. T., and Nair, M. G. Activity of the new antifolate jVIO-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase and KB cells containing different levels of dihydrofolate reductase. Cancer Res., 45:598-600, 1985.
5. Cheng, Y-C., Ueda, T., Dutschman, G. E., Starnes, M. C., Fisher, M. H., Balzarini, J. M. R., and Bapat, A. R. ArIO-Propargyl-5,8-dideazafolate and its polyglutamates; inhibition of thymidylate synthase from human sources and cytotoxicity toward KB cell lines which contain different amounts of dihydrofolate reductase. In: 1. D. Goldman (ed.), Proceedings of the Second Workshop on Folyl and Antifolyl Polyglutamates. New York: Praeger Scientific, 1985.
6. Jackman, A. L., Jones, T. R., and Calvert, A. H. Thymidylate synthase inhibitors: experimental and clinical aspects. In: F. M. Muggia (ed.), Experimental and Clinical Progress in Cancer Chemotherapy, pp. 155-210. Boston: Martinus Nijhoff, 1985.
7. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem. Pharmacol., 33:3269-3275, 1984.
8. Jackman, A. L., Calvert, A. H., Taylor, G. A., and Harrap, K. R. Biological properties of the new quinazoline inhibitor of thymidylate synthetase, CB3717. In: W. Davis, C. Maltoni, and S. Tanneberger (eds.), Tumour Growth and Its Biological Bases, pp. 404-410. Berlin: Academie Verlag, 1983.
9. Diddens, H., Niethammer, D., and Jackson, R. C. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res., 43: 5286-5292, 1983.
10. Jackman, A. L., Taylor, G. A., O'Connor, B. M., Bishop, J. A., Moran, R. G., and Calvert, A. H. Activity of the thymidylate synthase inhibitor 2-desamino-JVlo-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res., SO: 5212-5218, 1990.
11. Calvert, A. H., Alison, D. L. Harland, S. J., Robinson, B. A., Jackman, A. L., Jones, T. R., Newell, D. R., Siddik, Z. H., Wiltshaw, E., McElwain, T. J., Smith, I. E., and Harrap, K. R. A Phase 1 evaluation of the quinazoline antifolate thymidylate synthase inhibitor, VIO-propargyl-5,8-dideazafolic acid, CB3717. J. Clin. Oncol., 4: 1245-1252, 1986.
12. Cantwell, B. M., Earnshaw, M., and Harris, A. L. Phase II study of a novel antifolate, W-propargyl-5,8-dideazafolic acid (CB3717), in a malignant mesothelioma. Cancer Treat. Rep., 70: 1335-1338, 1986.
13. Bassendine, M. F., Curtin, N. J., Loose, H., Harris, A. L., and James, O. F. W. Induction of remission to hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717: a Phase II study. J. Hepatol., 4: 349-356, 1987.
14. Calvert, A. H., Newell, D. R., Jackman, A. L., Gumbell, L. A., Sikora, E., Grzelakowska-Sztabert, B., Bishop, J. A. M., Judson, I. R., Harland, S. J., and Harrap, K. R. Recent preclinical and clinical studies with the thymidylate synthase inhibitor JV10-propargyl-5,8-dideazafolic acid (CB3717). Natl. Cancer Inst. Monogr., 5: 213-218,1987.
15. Vest, S., Bork, E., and Hansen, H. H. A Phase 1 evaluation of JVl0-propargyl-5,8-dideazafolic acid. Eur. J. Cancer Clin. Oncol., 24:201-204, 1988.
16. Cantwell, B. M. J., Macaulay, V., Harris, A. L., Kaye, S. B., Smith, I. E., Milstead, R. A. V., and Calvert, A. H. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur. J. Cancer Clin. Oncol., 24: 733-736, 1988.
17. Sessa, C., Zucchetti, Ginier, M., Willems, Y., D'Incalci, M., and Cavalli, F. Phase 1 study of the antifolate 7V,0-propargyl-5,8-dideazafolic acid, CB3717. Eur. J. Cancer Clin. Oncol., 24: 769-775, 1988.
18. Newell, D. R., Alison, D. L., Calvert, A. H., Harrap, K. R., Jarman, M., Jones, T. R., Manteuffel-Cymborowska, M., and O'Connor, P. Pharmacokinetics of the thymidylate synthase inhibitor W'-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat. Rep., 70:971-979, 1986.
19. Alison, D. L., Newell, D. R., Sessa, C., Harland, S. J., Hart, L. I., Harrap, K. R., and Calvert, A. H. The clinical pharmacokinetics of the novel antifolate Afl0-propargyl-5,8-dideazafolic acid (CB3717). Cancer Chemother. Pharmacol., 14:265-271,1985.
20. Jones, T. R., Thornton, T. J., Flinn, A., Jackman, A. L. Newell, D. R., and Calvert, A. H. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J. Med. Chem., 32:847-852, 1989.
21. Jackman, A. L., Newell, D. R., Taylor, G. A., O'Connor, B. M., Hughes, L. R., and Calvert, A. H. 2-Desamino-10-propargy 1-5,8-dideazafolic acid (desamino-CB3717) a thymidylate synthase inhibitor, devoid of renal and hepatic toxicities in mice. Proc. Am. Assoc. Cancer Res., 28:271, 1987.
22. Jackman, A. L., Newell, D. R., Gibson, W., Jodrell, D. I., Taylor, G. A., Bishop, J. A., Hughes, L. R., and Calvert, A. H. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyI-7VIO-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem. Pharmacol., in press, 1991.
23. Hughes, L. R., Marsham, P. R., Oldfield, J., Jones, T. R., O'Connor, B. M., Bishop, J. A. M., Calvert, A. H., and Jackman, A. L. Thymidylate synthase inhibitory and cytotoxic activity of a series of C2 substituted-5,8-deazafolates. Proc. Am. Assoc. Cancer Res., 29: 286, 1988.
24. Hughes, L. R., Jackman, A. L., Oldfield, J., Smith, R. C., Burrows, K. D., Marsham, P. R., Bishop, J. A. M., Jones, T. R., O'Connor, B. M., and Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J. Med. Chem., 33:3060-3067,1990.
25. Jackman, A. L., Taylor, G. A., Moran, R., Bishop, J. A. M., Bisset, G., Pawelczak, K., Balmanno, K., Hughes, L. R., and Calvert, A. H. Biological properties of 2-desamino-2-substituted-5,8-deazafolates that inhibit thymidylate synthase. Proc. Am. Assoc. Cancer Res., 29:287, 1988.
26. Marsham, P. R., Chambers, P., Hayter, A. J., Hughes, L. R., Jackman, A. L., O'Connor, B. M., Bishop, J. A. M., and Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur and chlorine substituents in the C2 position. J. Med. Chem., 32:569-575,1989.
27. Hughes, L. R., Marsham, P. R., Oldfield, J., Hayter, A. J., Jackman, A. L., O'Connor, B. M., Bishop, J. A. M., and Calvert, A. H. Replacement of the para-aminobenzoyl portion of a series of C2-desamino-C2-methyl-dideaza-folic acid derivatives: effect on thymidylate synthase inhibition and cytotoxicity. Proc. Am. Assoc. Cancer Res., 30:476,1989.
28. Marsham, P. R., Hughes, L. R., Jackman, A. L., Hayter, A. J., Oldfield, J., Wardleworth, J. M., Bishop, J. A., O'Connor, B. M., and Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J. Med. Chem., 34:1594-1605, 1991.
29. Marsham, P. R., Hughes, L. R., Hayter, A. J., Oldfield, J., Jackman, A. L., Bishop, J. A., O'Connor, B. M., and Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: potent cytotoxic agents containing heterocyclic isosteres of the para-aminobenzoate unit. In: H-C. Curtius, S. Ghisla, and N. Blau (eds.), Chemistry and Biology of Pteridines 1989, pp. 1048-1051. Berlin: Walter de Gruyter & Co., 1990.
30. Jackman, A. L., Marsham, P. R., Moran, R. G., Kimbell, R., O'Connor, B. M., Hughes, L. R., and Calvert, A. H. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-jYl0-substituted-5,8-dideazafolates. Adv. Enzyme Regul., 31: 13-27, 1991.
31. Jackman, A. L., Taylor, G. A., Bishop, J. A., O'Connor, B. M., Bisset, G., Hughes, L. R., Moran, R. G., and Calvert, A. H. Biochemical aspects of a new thymidylate synthase inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31:342, 1990.
32. Jodrell, D. I., Newell, D. R., Calvete, J. A., Stephens, T. C., and Calvert, A. H. Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31: 341, 1990.
33. Stephens, T. C., Calvete, J. A., Janes, D., Waterman, S. E., Valcaccia, B. E., Hughes, L. R., and Calvert, A. H. Antitumor activity of new thymidylate synthase inhibitor, D1694. Proc. Am. Assoc. Cancer Res., 31:342,1990.
34. Bisset, G. M. F., Pawelczak, K., Jackman, A. L., Calvert, A. H., and Hughes, L. R. The synthesis and thymidylate synthase inhibitory activity of the poly-7-glutamyl conjugates of ICI D1694 and other quinazoline antifolates. J. Med. Chem., in press, 1991.
35. Goldstein, A. The mechanisms of enzyme-inhibitor-substrate reactions. J. Gen. Physiol., 27:529-580, 1944.
36. SAS. SAS User's Guide: Statistics, Version 5, pp. 575-606. Cary, NC, SAS Institute, Inc., 1985.
37. Calvert, A. H., Jones, T. R., Dady, P. J., Grzelakowska-Sztabert, B., Paine, R. M., Taylor, G. A., and Harrap, K. R. Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. Eur. J. Cancer., 16: 713-722, 1980.
38. Yalowich, J. C., and Kalman, T. I. Rapid determination of thymidylate synthase activity and its inhibition in intact LI210 leukemia cells in vitro. Biochem. Pharmacol., 34: 2319-2324,1985.
39. Nicander, B., and Reichard, P. Dynamics of pyrimidine deoxynucleoside triphosphate pools in relationship to DNA synthesis in 3T6 mouse fibroblasts. Proc. Natl. Acad. Sci. USA, 80:1347-1351,1983.
40. Taylor, G. A., Jackman, A. L., Balmanno, K., Hughes, L. R., and Calvert, A. H. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells. In: K. Mikanagi, K. Nifhioka, and W. N. Kelley (eds.), Purine Metabolism in Man, Vol. 6, pp. 383-388. New York: Plenum Publishing Corp., 1989.
41. Orr, R. M., Peacock, J., Payne, A. W. R., Goddard, P. M., and Harrap, K. R. In vitro sensitivities of diploid and tetraploid LI 210 cell lines to antineoplastic agents. In: G. K. Daikos and H. Giamarellou (eds.), Chemioterapia, Vol. 4, pp. 1178-1179. Florence: II Sedicesimo, 1985.
42. Sikora, E., Jackson, A. L., Newell, D. R., and Calvert, A. H. Formation and retention and biological activity of W-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in LI210 cells in vitro. Biochem. Pharmacol., 37: 4047-4054, 1988.
43. Sikora, E., Jackman, A. L., Newell, D. R., Harrap, K. R., Calvert, A. H., Jones, T. R., Pawelczak, K., and Rzeszotarska, B. jV10-propargyl-5,8-dideazafolic acid polyglutamates as inhibitors of thymidylate synthase and their intracellular formation. In: B. A. Cooper and V. M. Whitehead (eds.), Chemistry and Biology of Pteridines, pp. 675-679. Berlin: Walter de Gruyter & Co., 1986.
44. Pawelczak, K., Jones, T. R., Kempny, M., Jackman, A. L., Newell, D. R., Krzyzanowski, L., and Rzeszotarska, B. Quinazoline antifolates inhibiting thymidylate synthase: synthesis of four oligo(L-7-glutamyl) conjugates of JVl0-propargyl-5,8-dideazafolic acid and their enzyme inhibition. J. Med. Chem., 32: 160-165, 1988.
45. Jackman, A. L., Calvert, A. H., and Moran, R. G., The reversal of the cytotoxicity of folate-based thymidylate synthase inhibitors in cultured LI 210 cells. In: B. A. Cooper and V. M. Whitehead (eds.), Chemistry and Biology of Pteridines, pp. 645-649. Berlin: Walter de Gruyter & Co., 1986.
46. O'Connor, B. M., Jackman, A. L., Crossley, P. H., and Calvert, A. H. Gene amplification as a mechanism of resistance to a novel folate-based thymidylate synthase inhibitor in human W1-L2 cells. Br. J. Cancer, 58:237,1988.
47. Patil, S. D., Jones, C., Nair, M. G., Galivan, J., Maley, F., Kisliuk, R. L., Gaumont, Y., Duch, D., and Ferone, R. Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-/V,0-propargyl-5,8-dideazafolic acid and related compounds. J. Med. Chem., 32: 1284-1289,1989.
48. Jansen, G., Schomagel, J. H., Westerhof, G. R., Rijkson G. R., Newell, D. R., and Jackman, A. L. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer ResM 50:7422-7548, 1990.
49. Jackman, A. L., Brown, M., Kelland, L., Gibson, W., Abel, G., Boyle, F. T., and Judson, I. Proc. Am. Assoc. Cancer Res., 32:326, 1991.
50. Moran, R. G., Baldwin, S. W., Taylor, E. C., and Shih, C. The 6-S and 6-R diastereoisomers of 5,10-dideaza-5,6,7,8-tetrahydrofoIate are equiactive inhibitors of de novo purine synthesis. J. Biol. Chem., 264: 21047-21051, 1989.
51. Pizzomo, G., Cashmore, A. R., Moroson, B. A., and Beardsley, G. P. Leucovorin: a “rescue” agent for 6(/?)5,10-dideazatetrahydrofolic acid (DDATHF). Proc. Am. Assoc. Cancer Res., 31: 339,1990.
52. Stephens, T. C., Valaccia, B. E., Sheader, M. L., Hughes, L. R., and Jackman, A. L. The thymidylate synthase inhibitor ICI D1694 is superior to CB3717, 5-flourouracil and methotrexate against a panel of human tumor xenografts. Proc. Am. Assoc. Cancer Res., 32:328,1991.
53. Fry, D. W., Besserer, J. A., and Boritzki, T. J. Transport of antitumor antibiotic CI-920 into LI210 leukemia cells by the reduced folate carrier system. Cancer Res., 44:3366-3370,1984.